Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 

Online Report Subscribers, Click Here

Pricing and Ordering Information

 

U.S. Neurostimulation Devices Market
Report #A592
- March 2013
167 Pages – 49 Exhibits – 8 Company Profiles


The U.S. market for implantable neurostimulation devices has grown significantly over the past decade, reaching nearly $1.9 billion in 2012. This unusually high-growth medical device market—which includes implantable neurostimulators or neuromodulation devices for deep brain stimulation (DBS), gastric nerve stimulation (GNS), sacral nerve stimulation (SNS), spinal cord stimulation (SCS), and vagus nerve stimulation (VNS); as well as one of the original neurostimulation markets, cochlear implants—is expected to expand at a strong compound annual growth rate of more than 13%, reaching nearly $3.5 billion by 2017, increasing by more than $1.6 billion over a span of 5 years.

Despite the lingering economic uncertainty and budgetary constraints that have restrained other medical device markets, the U.S. market for neurostimulation devices is expected to experience double-digit growth due to several factors, including cost-efficiency, strong reimbursement and device replacement sales. Growth is supported by continued success and strong demand for leading neurostimulation systems developed by major competitors including Medtronic, Boston Scientific, St. Jude Medical, Cyberonics and Cochlear, Ltd. that provide safe and effective long-term therapies for a large, diversified and aging population of patients who suffer from intractable/refractory conditions such as epilepsy, chronic pain of the trunk or limbs, incontinence and Parkinson's disease. New, exciting applications will help expand the market over the next decade, including those that may treat certain forms of blindness; severe, refractory chronic migraine; morbid obesity; and obstructive sleep apnea, among other indications.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, emerging technology and opportunities. Covered products include neurostimulation devices for the core treatment areas: chronic intractable pain, dystonia/essential tremor/Parkinson's disease, refractory epilepsy, gastroparesis, profound hearing loss, urinary (overactive bladder) and fecal incontinence, as well as several emerging applications, including blindness, chronic migraine, treatment-resistant depression, heart failure, obesity, sleep apnea (obstructive), foot drop, paralysis, stroke and tinnitus, among others. The report also discusses a handful of emerging noninvasive stimulation technologies, such as peripheral nerve stimulation for the treatment of chronic pain.

Ordering Information

Title

Report# Publication
Date
List Price

U.S. Neurostimulation Devices Market

A592

March 2013

$4,750

Order Online:
Single User only (Please call for corporate subscription pricing)
PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

 

EXECUTIVE SUMMARY

i.       Implantable Neurostimulation Devices Market

a.      Market Forecast

ii.       Methodology

 

Exhibit ES-1:    Estimated Prevalence of Selected Neurological Conditions

Exhibit ES-2:    Selected Advantages and Disadvantages of Neurostimulation Therapy

Exhibit ES-3:    Estimated Number of Neurostimulation Implants, by Selected Neurological Condition

Exhibit ES-4:    Selected Market Drivers and Limiters for Implantable Neurostimulation Devices

Exhibit ES-5:    Implantable Neurostimulation Devices (Including Cochlear Implants), Combined Market Forecast 2012-2017

Exhibit ES-6:    Implantable Neurostimulation Devices (Excluding Cochlear Implants), Combined Market Forecast, 2012-2017

Exhibit ES-7:    Cochlear Implants, Market Forecast, 2012-2017

 

1. NEUROSTIMULATION TECHNOLOGIES OVERVIEW

1.1 Implantable Neurostimulators

1.1.1 Deep Brain Stimulators

1.1.2 Gastric Nerve Stimulators

1.1.3 Sacral Nerve Stimulators

1.1.4 Spinal Cord Stimulators

1.1.5 Vagus Nerve Stimulators

1.1.6 Cochlear Implants

 

Exhibit 1-1:      Estimated Prevalence of Selected Neurological Conditions

Exhibit 1-2:      Selected Advantages and Disadvantages of Neurostimulation Therapy

Exhibit 1-3:      Estimated Number of Neurostimulation Implants, by Selected Neurological Condition

Exhibit 1-4:      Schematic Illustration of Deep Brain Stimulation

 

2. NEUROSTIMULATION DEVICES

2.1 Applications for Implantable Neurostimulators

2.1.1 Chronic Pain

2.1.1.1 Boston Scientific

2.1.1.2 Medtronic

2.1.1.3 St. Jude Medical

2.1.2 Dystonia, Essential Tremor, and Parkinson’s Disease

2.1.2.1 Boston Scientific

2.1.2.2 Medtronic

2.1.2.3 St. Jude Medical

2.1.3 Epilepsy

2.1.3.1 CerebralRx/BioControl Medical

2.1.3.2 Cyberonics

2.1.3.3 Medtronic

2.1.3.4 NeuroPace

2.1.3.5 NeuroSigma

2.1.3.6 NeuroVista

2.1.4 Gastroparesis

2.1.4.1 Medtronic

2.1.5 Hearing Loss

2.1.5.1 Advanced Bionics/Sonova Holding

2.1.5.2 Cochlear

2.1.5.3 MED-EL

2.1.6 Incontinence

2.1.6.1 Medtronic

 

Exhibit 2-1:      2013, Leading Competitors in the Neurostimulation Market and the Applications for Their Products, by Condition

Exhibit 2-2:      The MyStim, Prime, and Restore Lines of Neurostimulators for the Treatment of Chronic Pain

Exhibit 2-3:      The Eon and Genesis Lines of Neurostimulators for the Treatment of Chronic Pain

Exhibit 2-4:      The Activa Neurostimulator for the Treatment of Parkinson’s Disease and Essential Tremor

Exhibit 2-5:      The VNS Therapy System for the Treatment of Epilepsy

Exhibit 2-6:      Responsive Neurostimulation for the Suppression of Epileptic Seizures

Exhibit 2-7:      The Seizure Advisory System for the Prediction of Epileptic Seizures

Exhibit 2-8:      The Enterra Gastric Neurostimulator for the Treatment of Gastroparesis

Exhibit 2-9:      The HiRes 90K Implant System for the Treatment of Hearing Loss

Exhibit 2-10:    The Nucleus Cochlear Implant System for the Treatment of Hearing Loss

Exhibit 2-11:    The MAESTRO Cochlear Implant System and OPUS 2XS Audio Processor for the Treatment of Hearing Loss

Exhibit 2-12:    The InterStim Therapy System for the Treatment of Incontinence

 

3. EMERGING NEUROSTIMULATION PRODUCTS AND TECHNOLOGIES

3.1 Applications for Emerging Implantable Neurostimulators

3.1.1 Blindness

3.1.1.1 Second Sight Medical Products

3.1.1.2 Others

3.1.1.2.1 Bionic Vision Australia

3.1.1.2.2 Intelligent Medical Implants

3.1.1.2.3 Retina Implant

3.1.2 Chronic Depression

3.1.2.1 Cyberonics

3.1.2.2 Medtronic

3.1.2.3 Northstar Neuroscience

3.1.2.4 St. Jude Medical

3.1.3 Chronic Heart Failure

3.1.3.1 Medtronic

3.1.3.2 Neurotech/Sorin Group

3.1.4 Chronic Migraine Headache

3.1.4.1 Boston Scientific

3.1.4.2 Medtronic

3.1.4.3 St. Jude Medical

3.1.5 Obesity

3.1.5.1 EnteroMedics

3.1.5.2 IntraPace

3.1.5.3 MetaCure

3.1.5.4 Others

3.1.6 Sleep Apnea

3.1.6.1 Apnex Medical

3.1.6.2 Avery Biomedical Devices

3.1.6.3 ImThera Medical

3.1.6.4 Inspire Medical Systems

3.1.6.5 Respicardia

3.1.7 Other Applications

3.1.7.1 Foot Drop

3.1.7.1.1 Neurostream Technologies/Otto Bock Group

3.1.7.2 Spinal Cord Injury

3.1.7.2.1 BrainGate Company

3.1.7.2.2 Synapse Biomedical

3.1.7.3 Stroke

3.1.7.4 Tinnitus

3.1.7.4.1 MicroTransponder

3.1.7.4.2 Silere Medical Technology

3.2 Applications for Noninvasive Peripheral Nerve Stimulation

3.2.1 The Magstim Company

3.2.2 Neuronetics

3.2.3 SPR Therapeutics

3.3 Applications for Noninvasive Transcutaneous Electrical Nerve Stimulation

3.3.1 Cerbomed

3.3.2 NeuroMetrix

 

Exhibit 3-1:      The Argus Line of Intraocular Retinal Prostheses

Exhibit 3-2:      Bionic Vision Australia’s Retinal Stimulation Technology

Exhibit 3-3:      Retina Implant’s Subretinal Implant Technology

Exhibit 3-4:      The Maestro VBLOC Therapy System and Vagus Nerve Function

Exhibit 3-5:      The abiliti Gastric Stimulation System for the Treatment of Obesity

Exhibit 3-6:      The DIAMOND for the Treatment of Obesity

Exhibit 3-7:      The Apnex Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnea

Exhibit 3-8:      The Mark IV Breathing Pacemaker System for the Treatment of Chronic Respiratory Insufficiency

Exhibit 3-9:      The aura6000 System for the Treatment of Obstructive Sleep Apnea

Exhibit 3-10:    An Illustration of Normal and Abnormal Breathing Patterns in Patients with Central Sleep Apnea

Exhibit 3-11:    The Neurostep System for the Treatment of Gait Disorders

Exhibit 3-12:    The Serenity System for the Treatment of Tinnitus

Exhibit 3-13:    The TheraStim 6000 Electronic Neurostimulation Device for the Treatment of Tinnitus

Exhibit 3-14:    The NeuroStar TMS Therapy System for the Treatment of Depression

Exhibit 3-15:    The Smartpatch PNS System for the Treatment of Chronic Shoulder Pain

Exhibit 3-16:    The SENSUS Pain Management System for the Treatment of Chronic Intractable Pain

 

4. IMPLANTABLE NEUROSTIMULATION DEVICES, MARKET ANALYSIS

4.1 Market Forecast

4.2 Implantable Neurostimulators, Competitive Analysis

4.3 Cochlear Implants, Competitive Analysis

4.4 Emerging Neurostimulation Technologies

 

Exhibit 4-1:      Selected Market Drivers and Limiters for Implantable Neurostimulation Devices

Exhibit 4-2:      Implantable Neurostimulation Devices (Including Cochlear Implants), Combined Market Forecast 2012-2017

Exhibit 4-3:      Implantable Neurostimulation Devices (Excluding Cochlear Implants), Combined Market Forecast, 2012-2017

Exhibit 4-4:      Cochlear Implants, Market Forecast, 2012-2017

Exhibit 4-5:      2012, Implantable Neurostimulation Devices Market, Estimated Percentage of Sales, by Application

Exhibit 4-6:      2012, Implantable Neurostimulation Devices Market (Including Cochlear Implants), Share by Supplier

Exhibit 4-7:      2012, Implantable Neurostimulation Devices Market (Excluding Cochlear Implants), Share by Supplier

Exhibit 4-8:      2012, Cochlear Implants Market, Share by Supplier

Exhibit 4-9:      Selected Neurostimulation Devices Expected to Launch in 2013-2014

Exhibit 4-10:    Selected Neurostimulation Devices Expected to Launch by the Year 2017

 

5. COMPANY PROFILES

5.1       Advanced Bionics Corporation/Sonova Holding AG

5.2       Boston Scientific Corporation

5.3       Cochlear LTD

5.4       Cyberonics, Inc.

5.5       EnteroMedics, Inc.

5.6       Medtronic, Inc.

5.7       Second Sight Medical Products, Inc.

5.8       St. Jude Medical, Inc.

 

APPENDIX: COMPANY LISTING

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact custcare@informa.com. You can also call 1.908.748.1221 (or toll-free within the U.S. at 1.888.670.8900) or fax 1.646.666.9878.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home